Press releases

Clinical study data on switching haemophilia A and B patients from on-demand treatment to extended half-life (EHL) prophylaxis showed a positive impact on clinical outcomes, with improvements in quality of life (QoL) and reduced annual bleeding rates (ABR). The results...

07/09/2019 - 08:00

On 17 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2019. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day...

07/08/2019 - 13:00

Interim results from verITI-8, an ongoing prospective, phase 4 study evaluating the efficacy of Elocta® (efmoroctocog alfa), for first-time Immune Tolerance Induction (ITI) for people with severe haemophilia A with inhibitors were presented today. These early data from...

07/08/2019 - 08:15

People with haemophilia have an increased risk of acute and chronic pain, and long-term disability, associated with bleeds. Anxiety and depression are other factors negatively affecting their quality of life. These were among the results of the MIND study, which aims to...

07/08/2019 - 08:00

Sobi™ presents data at the ISTH 2019: The 27th Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, 6 – 10 July 2019, focusing on the use of Elocta® and Alprolix® in clinical settings such as treatment switches from on demand to...

06/25/2019 - 13:45

Press contacts

Subscribe to our press releases and financial reports